Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:BLUA NASDAQ:DCTH NASDAQ:RXST NASDAQ:TMCI On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBLUABlueRiver Acquisition$11.09$10.26▼$11.45$96.90MN/A26,528 shs16,400 shsDCTHDelcath Systems$11.27+6.4%$13.45$7.17▼$18.23$368.81M0.82717,210 shs576,408 shsRXSTRxSight$7.92+1.5%$11.75$6.32▼$58.23$316.97M1.162.18 million shs757,737 shsTMCITreace Medical Concepts$5.61+5.1%$5.82$4.54▼$10.79$335.83M0.68258,505 shs318,017 shsOptions Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBLUABlueRiver Acquisition0.00%0.00%0.00%0.00%0.00%DCTHDelcath Systems+6.42%-1.23%-11.43%-3.84%+38.79%RXSTRxSight+1.54%+0.64%-40.00%-43.23%-81.04%TMCITreace Medical Concepts+5.06%-2.43%-7.29%-23.98%-15.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBLUABlueRiver AcquisitionN/AN/AN/AN/AN/AN/AN/AN/ADCTHDelcath Systems2.9873 of 5 stars3.52.00.00.03.72.50.6RXSTRxSight3.3753 of 5 stars4.04.00.00.02.81.70.6TMCITreace Medical Concepts2.3815 of 5 stars3.21.00.00.02.73.30.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBLUABlueRiver Acquisition 0.00N/AN/AN/ADCTHDelcath Systems 3.00Buy$24.00112.95% UpsideRXSTRxSight 1.91Reduce$17.50120.96% UpsideTMCITreace Medical Concepts 2.33Hold$10.5287.46% UpsideCurrent Analyst Ratings BreakdownLatest BLUA, DCTH, TMCI, and RXST Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/15/2025RXSTRxSightMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeOverweight ➝ Equal Weight$20.00 ➝ $9.007/10/2025RXSTRxSightJefferies Financial GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Hold$24.00 ➝ $9.007/9/2025RXSTRxSightBank of AmericaSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetUnderperform ➝ Underperform$18.00 ➝ $9.007/9/2025RXSTRxSightPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$18.00 ➝ $10.007/9/2025RXSTRxSightStifel NicolausSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetHold ➝ Hold$17.00 ➝ $9.007/9/2025RXSTRxSightOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeOutperform ➝ Market Perform7/9/2025RXSTRxSightWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeOverweight ➝ Equal Weight$25.00 ➝ $9.007/9/2025RXSTRxSightNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$22.007/9/2025RXSTRxSightBTIG ResearchSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Neutral6/23/2025DCTHDelcath SystemsStephensSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight$25.005/23/2025DCTHDelcath SystemsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$24.00 ➝ $29.00(Data available from 8/5/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBLUABlueRiver AcquisitionN/AN/AN/AN/A($0.72) per shareN/ADCTHDelcath Systems$37.21M10.55N/AN/A$2.15 per share5.24RXSTRxSight$139.93M2.30N/AN/A$6.98 per share1.13TMCITreace Medical Concepts$209.36M1.69N/AN/A$1.81 per share3.10Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBLUABlueRiver Acquisition-$5.28MN/A0.00N/AN/AN/AN/A-34.53%N/ADCTHDelcath Systems-$26.39M-$0.50N/AN/AN/A-26.38%-29.44%-20.75%8/6/2025 (Estimated)RXSTRxSight-$27.45M-$0.67N/AN/AN/A-17.90%-9.54%-8.51%8/7/2025 (Estimated)TMCITreace Medical Concepts-$55.74M-$0.85N/AN/AN/A-25.14%-48.69%-24.59%8/7/2025 (Estimated)Latest BLUA, DCTH, TMCI, and RXST EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/7/2025Guidance UpdateRXSTRxSight-$0.0363N/AN/AN/A$39.78 millionN/A8/7/2025Q2 2025TMCITreace Medical Concepts-$0.28N/AN/AN/A$47.08 millionN/A8/6/2025Q2 2025DCTHDelcath Systems$0.02N/AN/AN/A$22.84 millionN/A5/8/2025Q1 2025DCTHDelcath Systems$0.10$0.03-$0.07$0.03$16.83 million$19.80 million5/8/2025Q1 2025TMCITreace Medical Concepts-$0.31-$0.25+$0.06-$0.25$52.07 million$52.57 million5/7/2025Q1 2025RXSTRxSight-$0.03-$0.03N/A-$0.20$38.74 million$37.90 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBLUABlueRiver AcquisitionN/AN/AN/AN/AN/ADCTHDelcath SystemsN/AN/AN/AN/AN/ARXSTRxSightN/AN/AN/AN/AN/ATMCITreace Medical ConceptsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBLUABlueRiver AcquisitionN/A0.010.01DCTHDelcath SystemsN/A15.9514.61RXSTRxSightN/A12.6811.65TMCITreace Medical Concepts0.514.503.36Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBLUABlueRiver Acquisition22.34%DCTHDelcath Systems61.12%RXSTRxSight78.78%TMCITreace Medical Concepts84.08%Insider OwnershipCompanyInsider OwnershipBLUABlueRiver Acquisition78.98%DCTHDelcath Systems17.94%RXSTRxSight9.57%TMCITreace Medical Concepts27.72%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBLUABlueRiver Acquisition38.73 million1.84 millionNot OptionableDCTHDelcath Systems6034.83 million28.58 millionOptionableRXSTRxSight22040.64 million36.75 millionOptionableTMCITreace Medical Concepts25062.89 million45.46 millionOptionableBLUA, DCTH, TMCI, and RXST HeadlinesRecent News About These CompaniesGSA Capital Partners LLP Buys Shares of 66,790 Treace Medical Concepts, Inc. (NASDAQ:TMCI)August 4 at 4:49 AM | marketbeat.comAnalysts Set Treace Medical Concepts, Inc. (NASDAQ:TMCI) Price Target at $10.52August 4 at 2:27 AM | americanbankingnews.comTreace Medical Concepts, Inc. (NASDAQ:TMCI) Given Average Rating of "Hold" by BrokeragesAugust 1, 2025 | marketbeat.comTreace Medical Concepts (TMCI) to Release Quarterly Earnings on ThursdayJuly 31, 2025 | marketbeat.comLegato Capital Management LLC Purchases Shares of 56,220 Treace Medical Concepts, Inc. (NASDAQ:TMCI)July 26, 2025 | marketbeat.comKornitzer Capital Management Inc. KS Sells 161,525 Shares of Treace Medical Concepts, Inc. (NASDAQ:TMCI)July 16, 2025 | marketbeat.comTreace Medical Concepts, Inc. Common Stock (TMCI) - NasdaqJuly 9, 2025 | nasdaq.comTreace Medical Concepts, Inc. (NASDAQ:TMCI) Given Average Recommendation of "Hold" by AnalystsJuly 7, 2025 | marketbeat.comTMCI Treace Medical Concepts, Inc. - Seeking AlphaJune 24, 2025 | seekingalpha.comTreace Medical Concepts, Inc. (NASDAQ:TMCI) is favoured by institutional owners who hold 53% of the companyJune 21, 2025 | finance.yahoo.comAttention Long-Term Treace Medical Concepts, Inc. (™CI) Shareholders: Grabar Law Office is Investigating Claims on Your BehalfJune 13, 2025 | investing.comKuehn Law Encourages Investors of Treace Medical Concepts, Inc. to Contact Law FirmJune 11, 2025 | prnewswire.comSecurities Lawsuit Alert: Treace Medical Concepts, Inc. (TMCI) Investors - Contact Levi & Korsinsky Before June 10, 2025June 10, 2025 | accessnewswire.comATreace Medical Concepts, Inc. Investors: Please contact the Portnoy Law Firm to recover your losses; June 10, 2025 Deadline to file Lead Plaintiff MotionJune 10, 2025 | globenewswire.comSecurities Class Action Lawsuit Filed Against Treace Medical Concepts, Inc. (TMCI) - Levi & Korsinsky Represents ShareholdersJune 10, 2025 | accessnewswire.comATMCI INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Treace Medical Concepts, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action LawsuitJune 10, 2025 | globenewswire.comLost Money on Treace Medical Concepts, Inc. (TMCI)? Join Class Action Before June 10, 2025 - Contact Levi & KorsinskyJune 10, 2025 | accessnewswire.comAClass Action Filed Against Treace Medical Concepts, Inc. (TMCI) - June 10, 2025 Deadline to Join – Contact Levi & KorsinskyJune 10, 2025 | globenewswire.comTMCI DEADLINE TODAY: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Treace Medical Concepts, Inc. Investors to Secure Counsel Before Important June 10 Deadline in Securities Class Action - TMCIJune 10, 2025 | accessnewswire.comAFINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Treace MedicalJune 10, 2025 | businesswire.comDid You Lose Money on Treace Medical Concepts, Inc. (TMCI)? Levi & Korsinsky Urges Investors to Act Before June 10, 2025June 10, 2025 | accessnewswire.comANew MarketBeat Followers Over TimeMedia Sentiment Over TimeBLUA, DCTH, TMCI, and RXST Company DescriptionsBlueRiver Acquisition NYSE:BLUABlueRiver Acquisition Corp. does not have significant operations. The company focuses on effecting a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses. It intends to identify business opportunities in the field of technology, media, telecom, and entertainment industries. The company was incorporated in 2020 and is based in San Antonio, Texas.Delcath Systems NASDAQ:DCTH$11.27 +0.68 (+6.42%) Closing price 08/4/2025 04:00 PM EasternExtended Trading$11.20 -0.07 (-0.62%) As of 08/4/2025 08:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. Its clinical development program for HEPZATO is the FOCUS clinical trial for patients with metastatic hepatic dominant Uveal Melanoma to investigate objective response rate in metastatic uveal melanoma. It also provides HEPZATO as a stand-alone medical device under the CHEMOSAT Hepatic Delivery System trade name for Melphalan or CHEMOSAT for medical centers to treat a range of liver cancers in Europe. Delcath Systems, Inc. was incorporated in 1988 and is headquartered in New York, New York.RxSight NASDAQ:RXST$7.92 +0.12 (+1.54%) Closing price 08/4/2025 04:00 PM EasternExtended Trading$7.97 +0.05 (+0.64%) As of 08/4/2025 07:38 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.RxSight, Inc., a commercial-stage medical device company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States and internationally. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery. The company's RxSight system includes RxSight Light Adjustable Lens, a special photosensitive material that changes shape and power. RxSight light delivery device, an office-based light treatment device that delivers UV light in a programmed pattern to modify the LAL based on the visual correction needed to achieve desired vision after cataract surgery. It primarily serves cataract doctors. The company was formerly known as Calhoun Vision, Inc. and changed its name to RxSight, Inc. in February 2017. RxSight, Inc. was incorporated in 1997 and is headquartered in Aliso Viejo, California.Treace Medical Concepts NASDAQ:TMCI$5.61 +0.27 (+5.06%) Closing price 08/4/2025 04:00 PM EasternExtended Trading$5.61 0.00 (0.00%) As of 08/4/2025 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Treace Medical Concepts, Inc., a medical technology company, designs, manufactures, and markets medical devices in the United States. The company offers Lapiplasty 3D bunion correction system that combines instruments, implants, and surgical methods designed to surgically correct three planes of the bunion deformity. It also provides Lapiplasty mini-incision system designed to allow the Lapiplasty procedure to be performed through a 3.5cm incision. In addition, the company offers Adductoplasty system designed for reproducible realignment, stabilization, and fusion of the midfoot. Treace Medical Concepts, Inc. was founded in 2013 and is headquartered in Ponte Vedra, Florida. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas How 2 Deals in 48 Hours Changed Everything for Joby Aviation Here's Why Traders Turned Bullish on Boeing Stock Onsemi’s August Pullback Is a Signal to Buy for Tech Investors Strategy Insiders Buy In While Analysts Predict Big Upside Analysts Make a Quantum Bet on D-Wave's Cryogenic Packaging Yes, You Can Get Dividends in Tech: 3 Stocks With Yield + Upside MarketBeat Week in Review – 07/28 - 08/01 Alphabet Gains Momentum as Sentiment on Wall Street Improves Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
